# Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection

> **NCT02021656** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 384 (actual)

## Conditions studied

- Chronic HCV Infection

## Interventions

- **DRUG:** LDV/SOF

## Key facts

- **NCT ID:** NCT02021656
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-10
- **Primary completion:** 2017-07-08
- **Final completion:** 2017-09-29
- **Target enrollment:** 384 (ACTUAL)
- **Last updated:** 2020-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02021656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02021656, "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02021656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*